AUTHOR=Papapetropoulos Spyros , Pontius Angela , Finger Elizabeth , Karrenbauer Virginija , Lynch David S. , Brennan Matthew , Zappia Samantha , Koehler Wolfgang , Schoels Ludger , Hayer Stefanie N. , Konno Takuya , Ikeuchi Takeshi , Lund Troy , Orthmann-Murphy Jennifer , Eichler Florian , Wszolek Zbigniew K. TITLE=Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development JOURNAL=Frontiers in Neurology VOLUME=12 YEAR=2022 URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.788168 DOI=10.3389/fneur.2021.788168 ISSN=1664-2295 ABSTRACT=

A comprehensive review of published literature was conducted to elucidate the genetics, neuropathology, imaging findings, prevalence, clinical course, diagnosis/clinical evaluation, potential biomarkers, and current and proposed treatments for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare, debilitating, and life-threatening neurodegenerative disorder for which disease-modifying therapies are not currently available. Details on potential efficacy endpoints for future interventional clinical trials in patients with ALSP and data related to the burden of the disease on patients and caregivers were also reviewed. The information in this position paper lays a foundation to establish an effective clinical rationale and address the clinical gaps for creation of a robust strategy to develop therapeutic agents for ALSP, as well as design future clinical trials, that have clinically meaningful and convergent endpoints.